← Back to Screener
Septerna, Inc. Common Stock (SEPN)
Price$26.86
Favorite Metrics
Price vs S&P 500 (26W)4.52%
Price vs S&P 500 (4W)-1.43%
Market Capitalization$1.17B
All Metrics
P/CF (Annual)10.65x
Book Value / Share (Quarterly)$8.52
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$2.45
Price vs S&P 500 (YTD)-10.42%
Net Profit Margin (TTM)-106.37%
EPS (TTM)$-1.11
10-Day Avg Trading Volume0.33M
EPS Excl Extra (TTM)$-1.11
EPS (Annual)$-1.10
ROI (Annual)-12.80%
Cash / Share (Quarterly)$8.73
Revenue Growth QoQ (YoY)11276.42%
ROA (Last FY)-8.20%
Revenue Growth TTM (YoY)11722.02%
EBITD / Share (TTM)$-1.50
Operating Margin (TTM)-148.63%
Cash Flow / Share (Annual)$2.45
P/B Ratio3.07x
P/B Ratio (Quarterly)3.27x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)22.91x
ROA (TTM)-9.53%
EPS Incl Extra (Annual)$-1.10
Current Ratio (Annual)4.73x
Quick Ratio (Quarterly)4.67x
3-Month Avg Trading Volume0.30M
52-Week Price Return336.23%
EV / Free Cash Flow (Annual)9.60x
Revenue / Employee (TTM)$0
P/S Ratio (Annual)25.54x
Asset Turnover (Annual)0.08x
52-Week High$32.63
EPS Excl Extra (Annual)$-1.10
26-Week Price Return13.26%
Quick Ratio (Annual)4.67x
13-Week Price Return-2.24%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.73x
Enterprise Value$1,052.682
Asset Turnover (TTM)0.09x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-106.35%
Cash / Share (Annual)$8.73
3-Month Return Std Dev61.17%
Net Income / Employee (TTM)$-0
ROE (Last FY)-12.80%
EPS Basic Excl Extra (Annual)$-1.10
Receivables Turnover (TTM)8.73x
EV / Free Cash Flow (TTM)9.60x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.11
Receivables Turnover (Annual)8.73x
ROI (TTM)-12.63%
P/S Ratio (TTM)25.54x
Revenue / Share (Annual)$1.04
Price vs S&P 500 (52W)301.13%
Year-to-Date Return-6.28%
5-Day Price Return11.95%
EPS Normalized (Annual)$-1.10
Net Profit Margin (Annual)-106.37%
Month-to-Date Return8.74%
EBITD / Share (Annual)$-1.51
Operating Margin (Annual)-148.63%
P/CF (TTM)10.65x
EPS Basic Excl Extra (TTM)$-1.11
P/B Ratio (Annual)3.27x
Pretax Margin (TTM)-106.35%
Book Value / Share (Annual)$8.52
Price vs S&P 500 (13W)-5.11%
Beta2.12x
P/FCF (Annual)10.70x
Revenue / Share (TTM)$1.03
ROE (TTM)-12.63%
52-Week Low$5.73
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SEPNSepterna, Inc. Common Stock | 25.54x | 11722.02% | — | — | $26.86 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Septerna Inc is a clinical-stage biotechnology company developing oral small molecule therapies targeting G protein-coupled receptors (GPCRs) using its proprietary Native Complex Platform. The company's pipeline addresses endocrinology, immunology/inflammation, and metabolic diseases, with lead candidates including SEP-786 (PTH1R), SEP-631 (MRGPRX2), and programs in GLP-1R, GIPR, GCGR, and TSHR. By enabling drug discovery against historically challenging GPCR targets, Septerna aims to address conditions with significant unmet medical needs.